The preclinical and Phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

James D. Chalmers, Philipp Badorrek, Claudia Diefenbach, Harald Kögler, Wiebke Sauter, Stefan Kreideweiss, Jens M. Hohlfeld

Please cite this article as: Chalmers JD, Badorrek P, Diefenbach C, et al. The preclinical and Phase 1 development of the novel oral cathepsin C inhibitor BI 1291583. ERJ Open Res 2024; in press (https://doi.org/10.1183/23120541.00725-2023).

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2024. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
The preclinical and Phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

**Author list:** James D. Chalmers,¹ Philipp Badorrek,² Claudia Diefenbach,³ Harald Kögler,⁴ Wiebke Sauter,³ Stefan Kreideweiss,³ Jens M. Hohlfeld²,⁵,⁶

**Affiliations:** ¹Division of Molecular and Clinical Medicine, University of Dundee, Dundee, United Kingdom; ²Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany; ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ⁴Boehringer Ingelheim International GmbH, Ingelheim, Germany; ⁵Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; ⁶German Centre for Lung Research (DZL), Hannover, Germany

**Corresponding author:**

James Chalmers

Email: j.chalmers@dundee.ac.uk

**Take-home message:** Preclinical and Phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting Phase 2 trials in bronchiectasis patients

**Target journal:** *ERJ Open Research*

**Article type:** Research Letter

**Word count:** 1805/1200

**Key words:** “bronchiectasis”, “CatC inhibition”, “neutrophil-derived serine proteases”, “neutrophil elastase”, “neutrophilic inflammation”

**Specialty/areas of interest:** “airway diseases”, “bronchiectasis”, “CatC inhibition”, “lung disease”, “lung inflammation”, “neutrophils, inflammation”
To the Editor:

Bronchiectasis is a heterogeneous lung disease characterised by chronic inflammation, infection, impaired mucociliary clearance and progressive structural lung damage [1, 2]. These features interact in a “vicious vortex”, leading to exacerbations and declining pulmonary function with associated morbidity and mortality [1, 2].

Neutrophilic inflammation and an imbalance between neutrophil-derived serine proteases (NSPs; neutrophil elastase [NE], proteinase 3 [PR3] and cathepsin G) and their anti-proteases are central features of bronchiectasis [1, 3]. High, uncontrolled NSP levels, which have been shown to impair mucociliary clearance, drive mucus hypersecretion, cause structural lung damage and weaken host defences, thereby contributing to each component of the vicious vortex [3]. Effective blockade of NSPs could therefore ameliorate each of these components.

As cathepsin C (CatC; also known as dipeptidyl peptidase 1) activates NSPs in the bone marrow during myelopoiesis [4], CatC inhibition is expected to reduce NSP activity in the lungs of patients with bronchiectasis, thereby restoring the protease/antiprotease balance. No drug is currently licensed for the treatment of bronchiectasis; therefore, there is a high unmet need for a novel treatment that reduces inflammation and improves symptoms and quality of life. BI 1291583, a novel CatC inhibitor, is currently being investigated in a Phase 2 trial in adults with bronchiectasis (Airleaf™) [5, 6]. Here, we summarise the preclinical and Phase 1 development of BI 1291583.

Preclinical investigations involved in vitro assessment of the binding and inhibition of CatC and assessment of NSP inhibition. We assessed the binding kinetics of BI 1291583 to isolated human CatC using surface plasmon resonance (pH 4.5). To determine the specificity of BI 1291583 for CatC, we measured the inhibition of cathepsins C, B, F, H, K, L and S by conversion of fluorescent substrates. Additionally, we assessed the specificity of BI 1291583 against 33 unrelated proteases from four classes using enzyme assays and validated fluorometric or photometric techniques. To determine whether inhibition of CatC leads to inhibition of active NSP production, we measured NE
activity by the conversion of a fluorescent substrate in lysates of the human myeloid progenitor cell line U937 (which produces high levels of activated NE) exposed to increasing concentrations of BI 1291583. Finally, we assessed the *in vivo* inhibition of active NE and PR3 production by exposing mice to 0.00005-5mg/kg BI 1291583 once daily (QD) over 11 days, followed by bacterial lipopolysaccharide challenge. NSP activity was determined in bronchoalveolar lavage fluid (BALF) neutrophils by conversion of fluorescent substrates. Exposure to BI 1291583 in the target bone marrow compartment and plasma of the mouse model was measured via liquid chromatography-tandem mass spectrometry.

BI 1291583 bound human CatC in a covalent, reversible manner, with a mean dissociation constant of 0.43nM and a mean half-life of 5.19 minutes. CatC enzymatic activity was inhibited with a half-maximal inhibitory concentration (IC50) of 0.9nM and with high selectivity (>6,000-fold selectivity versus related cathepsins and no relevant inhibition or stimulation of unrelated proteases). Production of active NE in U937 cells was inhibited in a concentration-dependent manner with an IC50 of 0.7nM whilst maintaining a cell viability of 93–98%. In mice BALF neutrophils, production of active NE (Figure 1a) and PR3 was almost completely inhibited in a dose-dependent manner (99% and 94% in the 5mg/kg dose group, respectively). BI 1291583 distributed preferentially to the bone marrow, with a bone marrow to plasma exposure ratio of up to 100 at efficacious doses. The physicochemical properties of BI 1291583 (balanced basicity and partition coefficient) in combination with the strong binding affinity of BI 1291583 with CatC (KD of 0.43nM) are believed to have led to the high bone marrow-to-plasma distribution at efficacious doses.

Together, these results demonstrate that BI 1291583 is a highly potent inhibitor of CatC, leading to relevant inhibition of NSPs, and supporting further investigation. As such, we carried out five Phase 1 trials of BI 1291583 in healthy Caucasian adults: three single-blind, partially randomised, placebo-controlled, parallel-group trials, one of which investigated single rising doses (SRD) (1–40mg; N=54 [NCT03414008] [7]) and two of which investigated once-daily multiple rising doses (MRD) (1mg,
2.5mg; N=24 [NCT03868540] [8]; 5mg, 10mg; N=24 [NCT04866160] [9]); an open-label, randomised, single-dose, two-period, two-sequence crossover bioavailability study investigating subjects under fed and fasted conditions (7.5mg; N=12 [NCT03837964] [10]); and an open-label, 2.5mg single-dose, two-period, fixed-sequence crossover drug–drug interaction study with and without itraconazole (N=14 [NCT03890887] [11]). As BI 1291583 is almost exclusively metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate of a P-glycoprotein (P-gp), inhibitors of these enzymes could result in clinically relevant increases in BI 1291583 exposure. As such, itraconazole, a strong CYP3A4 and P-gp inhibitor, was used in the drug–drug interaction study. The doses selected in the SRD study covered the assumed sub-therapeutic and therapeutic ranges, and included a safety margin; the doses selected in the MRD studies covered the assumed sub-therapeutic, therapeutic and supra-therapeutic ranges, and included a safety margin; the dose selected for the food-effect study was the assumed therapeutic dose at the time of study conduct; and a dose of 2.5 mg BI 1291583 was selected in the drug–drug interaction study in order to ensure that BI 1291583 plasma concentrations, even in the case of substantial increase when co-administered with itraconazole, were within the range of concentrations that were explored in the SRD trial and that had been associated with good safety and tolerability. Sample size was not based on a power calculation for any of the five Phase I trials; the same sizes selected were, in general, considered sufficient for the exploratory analyses performed, including the evaluation of safety and pharmacokinetics. Primary endpoints were investigator-judged drug-related adverse events (AEs) for the SRD and MRD studies, and BI 1291583 exposure for the food effect and drug–drug interaction studies. AEs of special interest (AESIs) included hyperkeratosis and periodontal disease; patients with Papillon–Lefèvre syndrome, a rare genetic disease caused by loss-of-function mutations in the CatC gene, often present with hyperkeratosis and severe periodontal disease [12], and these events should be monitored in trials of CatC inhibitors. However, complete loss of CatC enzymatic activity is not expected with BI 1291583. Secondary endpoints for all trials included pharmacokinetic parameters, as well as CatC and NE activity and PR3 amount in blood for the SRD and MRD studies specifically.
Across the trials, almost all the AEs reported were mild or moderate in intensity, with no reported serious AEs, AESIs or deaths. Two severe treatment-emergent AEs were reported (one gastrointestinal infection event [SRD study] and one joint injury event [food effect study]), and one patient was prematurely withdrawn due to AEs (C-reactive protein increased and thrombophlebitis), but all events were considered unrelated to BI 1291583. Similar rates of skin exfoliation, considered drug related by the investigator, were observed in the BI 1291583 versus placebo groups (MRD study 1: 2/18 vs 1/6; MRD study 2: 1/18 vs 0/6). No infections or changes in white blood cell counts were reported as being related to treatment. BI 1291583 was readily absorbed, and exposures increased supraproportionally over the dose range investigated (MRD studies), with an apparent terminal half-life of 60.2 hours (40mg dose). Exposure at 5mg exceeded that predicted by preclinical studies to be required for 99% inhibition of CatC. BI 1291583 exposure was generally similar under fed and fasted conditions; however, co-administration of BI 1291583 with multiple doses of itraconazole resulted in an approximate twofold increase in exposure. BI 1291583 inhibition of CatC was dose-dependent, with a maximum inhibition of 96% in the SRD 30mg dose group and 85% in the MRD 10mg dose group (Figure 1b). Subsequent inhibition of NE activity was observed, with a maximum inhibition of 86% (10mg dose; MRD study) (Figure 1c). Additionally, decreased levels of PR3 were observed, with a maximum decrease of 65% (10mg dose; MRD study) (Figure 1d).

In summary, preclinical studies demonstrate that BI 1291583 is a highly potent inhibitor of CatC that leads to marked inhibition of NE and PR3. Furthermore, it distributes to the target bone marrow compartment at an exposure up to 100x higher than in plasma at efficacious doses. Across the five Phase 1 trials in healthy subjects, BI 1291583 was found to be safe, well tolerated, and readily absorbed and to exhibit dose-dependent inhibition of CatC, thereby inhibiting downstream NE activity and decreasing PR3 levels.

To date, only two other CatC inhibitors have reached clinical trials in patients. HSK31858 is being assessed in a Phase 2 trial in patients with non-cystic fibrosis bronchiectasis (NCT05601778), and the
oral, reversible inhibitor bensocatib (formerly AZD7986/INS1007) is being assessed in a Phase 3 trial for patients with bronchiectasis (NCT04594369). In light of the published preclinical data for bensocatib [13], our data suggest that BI 1291583 may also be a promising candidate for bronchiectasis treatment. In the Phase 1 study of bensocatib [14], 25mg QD administration resulted in a 49% decrease in NE activity in blood; in the Phase 2 study, this dose resulted in ~90% inhibition of sputum NE activity [15] and in a subsequent exploratory analysis, a 53% inhibition of sputum PR3 activity was reported [16]. A recent pharmacokinetic/pharmacodynamic analysis of bensocatib [17] showed that patients achieving an NE level below the limit of quantification (BLQ) had a greatly reduced risk of exacerbation. However, even at the 25mg QD dose, many patients did not achieve an NE level BLQ. The high bone marrow:plasma distribution we have demonstrated in the mouse model may help to achieve greater proportions of patients with substantially suppressed airway NSPs. Indeed, in the Phase 1 trials, we observed a marked decrease in blood NE activity with a relatively low (5mg) dose of BI 1291583; therefore, this dose may result in high NE inhibition in sputum in Phase 2 studies. A 5mg dose of BI 1291583 also resulted in a 58% decrease in blood PR3 levels. This broad inhibition of NSPs may add further beneficial therapeutic potential in patients with bronchiectasis.

Marked skin desquamation events were partly responsible for the termination of a previous CatC inhibitor [18], and drug-related skin events are reported in Phase 1 and 2 trials of bensocatib [14, 15]. Skin events occur independently of the action of CatC in the bone marrow, and likely occur as a result of the role that CatC plays in the processing of keratins in keratinocytes, and thus in maintaining the structural integrity of plantar and palmar epidermal surfaces [19], rather than as a result of NSP inhibition. The lack of drug-related skin events during our Phase 1 trials, potentially due to high bone marrow:plasma distribution, reinforces the potential of BI 1291583.

In conclusion, BI 1291583 is a reversible, highly potent and highly selective inhibitor of CatC that markedly inhibits production of active NSPs in a dose-dependent manner. It is safe and well
tolerated and, crucially, did not increase the incidence of drug-related skin exfoliation. A multinational Phase 2 trial of BI 1291583 in adults with bronchiectasis is ongoing (Airleaf™) [5].

**Acknowledgements:** The authors would like to thank A. Eleftheraki for providing statistical support and C. Völk for acting as the clinical trial leader across all five trials.

**Author contributions:** J.D. Chalmers, P. Badorrek, C. Diefenbach, H. Kögl er, W. Sauter, S. Kreideweiss and J. M. Hohlfeld drafted the first version of the manuscript. All authors reviewed the manuscript critically for important intellectual content and provided final approval for submission.

**Conflict of interest:** J.D. Chalmers reports grant support from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Grifols, Insmed, Novartis and Zambon and consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Insmed, Pfizer and Zambon. P. Badorrek has nothing to disclose. C. Diefenbach, H. Kögl er, W. Sauter and S. Kreideweiss are employees of Boehringer Ingelheim. J. M. Hohlfeld reports grant support paid to his institution from AltamiraPharma GmbH, Astellas Pharma GmbH, AstraZeneca AB, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CSL Behring GmbH, Desitin Arzneimittel GmbH, EpiEndo, F. Hoffmann-La Roche AG, Genentech, Inc., M&P Pharma AG, Novartis AG, OM Pharma SA and Sanofi-Aventis Deutschland GmbH, personal fees for consultancy from Boehringer Ingelheim Pharma GmbH & Co. KG, Cureteq and Roche, personal fees for lectures from Novartis AG, and personal fees for board service from CSL Behring GmbH and Nocion.

**Support statement:** These trials and pre-clinical assessments are supported and funded by Boehringer Ingelheim International GmbH. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the letter. Laura Cottino, PhD, and Rose Martin, MRes, of Nucleus Global provided writing, editorial support and formatting assistance, which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to
review the manuscript for medical and scientific accuracy as well as intellectual property considerations.
References


7. ClinicalTrials.gov. This study tests how different doses of BI 1291583 are taken up in the body and how well they are tolerated. 2018 10/11/202 [cited 2023 February 2]; Available from: https://clinicaltrials.gov/ct2/show/NCT03414008?term=NCT03414008&draw=2&rank=1


Figure 1. Summary of key preclinical and Phase 1 data. a) Effect of treatment with BI 1291583 on NE activity in mouse BALF neutrophil lysate; b) Mean maximum percentage inhibition of CatC after multiple oral administrations of BI 1291583 in healthy volunteers; c) Mean maximum percentage inhibition of zymosan-stimulated neutrophil elastase activity after multiple oral administrations of BI 1291583; d) Mean maximum percentage reduction in PR3 amount after multiple oral administrations of BI 1291583.

***P<0.001 compared with vehicle. Data are mean. In a, error bars indicate standard error of the mean. In b–d, error bars indicate standard deviation.

BALF, bronchoalveolar lavage fluid; CatC, cathepsin C; LPS, lipopolysaccharide; NE, neutrophil elastase; p.o., orally; PR3, proteinase 3; RFU, relative fluorescence units; WBC, white blood count.